Frédéric Triebel, MD, PhD, Immutep, Paris, France, discusses the final results from the Phase IIb AIPAC trial (NCT02614833) which compared the soluble LAG-3 protein, eftilagimod alpha (IMP321), with placebo, in combination with paclitaxel in a double-blind setting for patients with hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer. Eftilagimod alpha is an active immunotherapy targeting CD8 T-cells. Younger patients (under 65 years of age) achieved better responses, due to immunosenescence being more common among older patients. The trial reported that the use of eftilagimod alpha resulted in higher levels of circulating CD8 T-cells in the blood, which suggests an improvement in activated immune response. There was a positive correlation between overall survival (OS) and the number of circulating CD8 T-cells. Dr Triebel emphasizes the high unmet need for effective therapies for patients with HR+ HER2- metastatic breast cancer who are undergoing first-line chemotherapy. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.
Dr Triebel is an employee of Immutep and owns Immutep’s stocks